Skip to main content
SpringerLink
Log in

Tumor Markers

  • Chapter
Surgery

  • 784 Accesses

Abstract

Surgery is currently the most common as well as the most effective modality used in the treatment of solid tumors. As a result, surgeons are often the primary caretakers of patients with cancer and are therefore intimately involved in many facets of cancer management including early diagnosis, formal primary tumor resection, monitoring for recurrence, and finally the assessment of prognosis and need for systemic adjuvant therapy. Significant resources have been expended to develop tools that can aid the clinician in caring for the cancer patient. One example is the use of serological tests that detect the presence of tumor markers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Gutman AB, Gutman EB. An “Acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Inves 1938; 17: 473.

    CAS  Google Scholar 

  2. Gold P, Freedman SO. Specific carcinoembryonic antigen of the human digestive system. J Exp Med 1965; 122: 467.

    PubMed  CAS  Google Scholar 

  3. Thompson DMP, Knipey J, Freedman SO, et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci, USA 1969; 64: 161.

    Google Scholar 

  4. Gold P, Shuster J, Freedman SO. Carcinoembryonic antigen (CEA) in clinical medicine. Historical perspectives, pitfalls, and projections. Cancer 1978; 42: 1399.

    PubMed  CAS  Google Scholar 

  5. Benchimol S, Guks A, Jothy S, Beauchemin N, Shirota K, and Stanners C. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327.

    PubMed  CAS  Google Scholar 

  6. Woolfson, K. Tumor Markers in Cancer of the Colon and Rectum. Dis Colon Rectum 1991; 34 (6): 506–511.

    PubMed  CAS  Google Scholar 

  7. Norton JA, Fraker DL. Tumor Markers. In: DC Sabiston, ed. Textbook of surgery. Philadelphia: WB Saunders, 1997; 534–553.

    Google Scholar 

  8. Go VI,. Carcinoembryonic antigen: clinical application. Cancer 1976; 37: 562–566.

    PubMed  CAS  Google Scholar 

  9. Herberman RB. Immunologic approaches to the diagnosis of cancer. Cancer 1976; 37: 549–562.

    PubMed  CAS  Google Scholar 

  10. Alpert ME, Uriel J, De Nechaud B. Alpha, fetoglobulin in the diagnosis of human hepatoma. N Engl J Mcd 1968; 278: 984.

    CAS  Google Scholar 

  11. Tomasi TB. Structure and function of alpha-fetoprotein. Annu Rev Med 1977; 28: 453.

    PubMed  CAS  Google Scholar 

  12. Taketa K. Alphafetoprotein: Reevaluation in hepatology. Hepatology 1990; 12: 1420.

    CAS  Google Scholar 

  13. Bloomer J, Waldman TA, McIntire R, et al. Alpha-fetoprotein in non-neoplastic hepatic disorders. JAMA 1975; 233: 38.

    PubMed  CAS  Google Scholar 

  14. Ravry M, McIntire R, Moertel CG, et al. Brief communication: Carcinoembryonic antigen and alpha-fetoprotein in the diagnosis of gastric and colonic cancer: A comparative clinical evaluation. J Natl Cancer Inst 1974; 52: 1019.

    PubMed  CAS  Google Scholar 

  15. Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematology/Oncology Clin North Am 1994; 8: 533–553.

    CAS  Google Scholar 

  16. Moorehead RJ, Hoper M, McKelvey ST. Assessment of ornithine decarboxylase activity in rectal mucosa as a marker for colorectal adenomas and carcinomas. Br J Surg 1987; 74: 364–365.

    PubMed  CAS  Google Scholar 

  17. Ruoslahti E, Engvall E, Pekkal A. Developmental changes in car-bohydrate moiety of human alpha-fetoprotein. Int J Cancer 1978; 22: 515.

    PubMed  CAS  Google Scholar 

  18. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma base on altered profile of alpha-fetoprotein. N Engl J Med 1993; 328: 1802.

    PubMed  CAS  Google Scholar 

  19. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA 19–9 in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704.

    PubMed  CAS  Google Scholar 

  20. Rits RE, Del Villano BC, Go VLW, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19–9 using the NCI serum bank. Int J Cancer 1984; 33: 339.

    Google Scholar 

  21. Lindmark G, Kressner U, Bergstrome R, et al Limited significance of serum tumor marker CA 72–4 in colorectal cancer. Anticancer Research 1996; 16: 895–898.

    PubMed  CAS  Google Scholar 

  22. van der Schouw YT, Verbeek ALM, Wobbes TH, et al. Comparison of four scrum tumour markes in the diagnosis of colorectal carcinoma. Br J Cancer 1992; 66: 148.

    PubMed  Google Scholar 

  23. Filella X, Molina R, Grau JJ, et al. Prognostic value of CA 19–9 levels in colorectal cancer. Ann Surg 1992; 216: 55.

    PubMed  CAS  Google Scholar 

  24. Begent RHJ. The value of carcinoembryonic antigen in clinical practice. BR J Hosp Med 1987;Apri1:335.

    Google Scholar 

  25. Fletcher, RH. Carcinoembryonic Antigen. Ann Int Med 1986; 104: 66–73.

    PubMed  CAS  Google Scholar 

  26. Wanebo HJ, Stearns M, Schwartz MK. Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer. Ann Surg 1978; 188: 481.

    PubMed  CAS  Google Scholar 

  27. Wolmark N, Fisher B, Wieand S, et al. The prognostic significance of preoperative carcinocmbryonic antigen levels in colorectal cancer. Ann Surg 1984; 199: 375.

    PubMed  CAS  Google Scholar 

  28. Moertel CG, O’Fallon JR, Go VLW, et al. The preoperative carcinoembryonic antigen test in the diagnosis, staging, and prognosis of colorectal cancer. Cancer 1990; 58: 603.

    Google Scholar 

  29. Arnaud JP, Koehl C, Adloff M. Carcinoembryonic antigen (CEA) in diagnosis and prognosis of colorectal carcinoma. Dis Colon Rectum 1980; 23: 141.

    PubMed  CAS  Google Scholar 

  30. Martin EW Jr, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. J Surg Res 1980; 28: 389–394.

    PubMed  Google Scholar 

  31. Minton JP, Hoehn JL, Gerber DM, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985; 55: 1284–1290.

    PubMed  CAS  Google Scholar 

  32. Steele G, Zamchek N, Wilson R, et al. Results of CEA-initiated second-look surgery for recurrent colorectal cancer. Am J Surg 1980; 139: 544.

    PubMed  Google Scholar 

  33. Staab HJ, Anderer FA, Stumpf E, et al. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients wtih recurrent gastrointestinal cancer. Am J Surg 1985; 149: 198.

    PubMed  CAS  Google Scholar 

  34. Martin EW Jr, Minton JP, and Carey LE. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985; 149: 202–310.

    Google Scholar 

  35. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. JAMA 1993; 270: 943.

    PubMed  CAS  Google Scholar 

  36. Martin EW, Jr., Minton JP and Carey LC. CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma. Ann Surg 1985; 202: 310.

    PubMed  Google Scholar 

  37. LaValle GJ, Chevinsky A, and Martin EW, Jr. Impact of radioimmuno-guided surgery. Semin Surg Oncol 1991; 167: 170.

    Google Scholar 

  38. Ravry M, Moertel CG, Schutt AJ, et al. Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinoma. Cancer 1974; 34: 1230.

    PubMed  CAS  Google Scholar 

  39. Nakayama T, Watanabe M, Teramoto T, et al. CA 19–9 as a predictor of recurrence in patients with colorectal cancer. J Surg Oncol 1997; 66 (4): 238–243.

    PubMed  CAS  Google Scholar 

  40. Von Kleist S, Hesse Y, Kananeeh H, et al. Comparative evaluation of four tumor markers, CA242, CA 19–9, TPA and CEA in carcinomas of the colon. Anticancer Res 1996; 16 (B): 2325–2331.

    Google Scholar 

  41. Carpelan-Holmstrom MA, Haglund CH, Roberts PJ. Differences in serum tumor markers between colon and rectal cancer. Comparison of CA 242 and carcinoembryonic antigen. Dis Colon Rectum 1996;39(7):799–805.

    PubMed  CAS  Google Scholar 

  42. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759.

    PubMed  CAS  Google Scholar 

  43. Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027.

    PubMed  CAS  Google Scholar 

  44. Jessup JM, Gallick GE. Current problems in cancer. In Steele G, Kinsella TJ (eds). The Biology of Colorectal Carcinoma. St. Louis: Mosby-Year Book, 1992; 263.

    Google Scholar 

  45. Powell SM, Petersen GM, Krush AJ, et al. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med 1993; 329: 1982.

    PubMed  CAS  Google Scholar 

  46. Pretlow TP, Brasitus TA, Fulton NC, et al. K-ras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 1993; 85: 2004.

    Google Scholar 

  47. Beasley RP, Hwang LY and Lin CC. Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22,707 men in Taiwan. Lancet 1981; 2: 1129.

    PubMed  CAS  Google Scholar 

  48. Heyward WL, Lanier AP, Bender TR. Early detection of primary hepatocellular carcinoma by screening for alpha-fetoprotein in high-risk families. Lancet 1983; 2: 1161.

    PubMed  CAS  Google Scholar 

  49. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797.

    PubMed  CAS  Google Scholar 

  50. Di Biscegile AM, Rustgi VK, Hoofnagle JH, et al. Hepatocellular Carcinoma. Ann Intern Med 1988; 108: 390.

    Google Scholar 

  51. Kobayashi T. Correlation between tumor markers and tumor size. Cancer Detection Prevention 1997; 10: 81–87.

    Google Scholar 

  52. Alpert E, Hershberg R, Schur PH, et al. alpha-Fetoprotein in human hepatoma: Improved detection in serum, and quantitative studies using a new sensitive technique. Gastroenterology. 1971; 61: 137.

    PubMed  CAS  Google Scholar 

  53. Matsumoto Y, Suzuki T, Ono H, et al. Response of alpha-fetoprotein to chemotherapy in patients with hepatomas. Cancer 1974; 34: 1602.

    PubMed  CAS  Google Scholar 

  54. Lopez JP, Balasegaram M, Thambyrajah V. Serum CA-125 as a marker of hepatocellular carcinoma. Int J Biological Markers. 1996; 11 (3): 178–182.

    CAS  Google Scholar 

  55. Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA 199 and CEA. Ann Clin Biochem 1998; 35 (1): 99–103.

    PubMed  Google Scholar 

  56. Jinno K, Tanimizu M, Hyodo I, et al. Circulating platelet-derived endothelial cell growth factor increases in hepatocellular carcinoma patients. Cancer 1998; 82 (7): 1260–1267.

    CAS  Google Scholar 

  57. Harmenberg U, Wahren B and Wiechel KL. Tumor markers carbohydrate antigens CA 19–9 and CA 50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreaticobiliary tract. Cancer Res 1988; 48: 1985.

    PubMed  CAS  Google Scholar 

  58. Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol 1990; 85: 350–355.

    PubMed  CAS  Google Scholar 

  59. Safi F, Beger H, Bittner R, et al. CA 19–9 and pancreatic adenocarcinoma. Cancer 1986; 57: 779.

    PubMed  CAS  Google Scholar 

  60. Forsmark C, Lambiase L, Vogel S. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19–9. Pancreas 1994; 9: 731–734.

    PubMed  CAS  Google Scholar 

  61. Ritts R, Nagomey D, Jacobsen D, et al. Comparison of preoperative serum CA 19–9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994; 9: 707–716.

    PubMed  Google Scholar 

  62. Lurdin J, Roberts PJ, Kuusel P, Hagland C. The prognostic value of preoperative serum levels of CA 19–9 and CEA in patients wtih pancreas cancer. B J Cancer 1994; 69 (3): 515–519.

    Google Scholar 

  63. Plebani M, Basso D, Panozzo M, et al. Tumor markers in the di-agnosis, monitoring and therapy of pancreatic cancer: state of the art. Int J Biol Markers 1995; 10: 189–199.

    PubMed  CAS  Google Scholar 

  64. Satake K, Chung Y-S, Umeyama K, et al. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. Cancer 1991; 68: 149–152.

    PubMed  CAS  Google Scholar 

  65. Tian F, Apert H, Myles J, et al. Prognostic value of serum CA 19–9 levels in pancreatic adenocarcinoma. Ann Surg 1992; 215: 350–355.

    PubMed  CAS  Google Scholar 

  66. Urban T, Ricci S, Grange J-D, et al. Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst 1993; 85: 2008.

    Google Scholar 

  67. Ravry M, McIntire R, Moertel CG, et al. Carcinoembryonic antigen and alpha-fetoprotein in the diagnosis of gastric and colonic cancer: A comparative clinical evaluation. J Natl Cancer Inst 1974; 54: 1019.

    Google Scholar 

  68. Spila A, Roselli M, Cosimelli M, et al. Clinical Utility of CA 72–4 serum marker in the staging and immediate post-surgical management of gastric cancer patients. Anticancer Res 1996; 16 (4): 2241–2247.

    PubMed  CAS  Google Scholar 

  69. Pectasides D, Mylonakis A, Kostopoulou M, et al. CEA, CA 199, CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997; 20 (4): 348–353.

    PubMed  CAS  Google Scholar 

  70. Bates SE, Longo DL. Tumor markers: value and limitations in the management of cancer patients. Cancer Treat Rev 1985; 12: 163–207.

    PubMed  CAS  Google Scholar 

  71. Kantoff PW, Talcott JA. The Prostate Specific Antigen, Its use as a tumor marker for prostate cancer. Hematol Oncol Clin North Am 1994; 8 (3): 555–572.

    PubMed  CAS  Google Scholar 

  72. Hara M, Inorre T, Fukuyama T. Some physico-chemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma. Japanese Journal of Legal Medicine 1971; 25: 322.

    PubMed  CAS  Google Scholar 

  73. Stamey, TA, Prestigiacomo, AF, Chen, Z. Standardization immunoassays for prostate specific antigen. Cancer, 1994; 74: 1662.

    PubMed  CAS  Google Scholar 

  74. Oesterling, JE, Jacobsen, SJ, Chute, CG, et al. Serum prostates-specific antigen in a community-based population of healthy men. JAMA, 1993; 270–680.

    Google Scholar 

  75. Benson MC, Olsson CA. Prostate specific antigen and prostate antigen density. Cancer 1994; 74: 1667.

    PubMed  CAS  Google Scholar 

  76. Smith, DS, and Catalona, WJ. Rate of change in serum prostate antigen levels as a method of prostate cancer detection. J Urol 1994; 152: 1163.

    PubMed  CAS  Google Scholar 

  77. Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1990; 147: 817–821.

    Google Scholar 

  78. Kantoff PW, Talcott JA. The Prostate Specific Antigen, its use as a tumor marker for prostate cancer. Hematol Oncol Clin North Am 1994; 8 (3): 555–572.

    PubMed  CAS  Google Scholar 

  79. Catalona WJ, Smith DS, Ratliff T, et al. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948–954.

    PubMed  CAS  Google Scholar 

  80. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110–114.

    PubMed  CAS  Google Scholar 

  81. Ablin RJ. A retrospective and prospective overview of prostate-specific antigen. J Cancer Res Clin Oncol 1997; 123: 583–594.

    PubMed  CAS  Google Scholar 

  82. Lange PH, Ercole CJ, Lightner DJ, et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 1989; 141: 873–879.

    PubMed  CAS  Google Scholar 

  83. Kuban DA, El-Mandi AM, Schellhammer PF. PSA for outcome prediction and post-treatment evaluation following radiation for prostate cancer: Do we know how to use it? Semin Radiation Oncol 1998; 8 (2): 72–80.

    CAS  Google Scholar 

  84. Seiden MV, Kantolf, PW, Krithivans, K. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994; 12: 2634.

    Google Scholar 

  85. Bast RC Jr, Hunter V, Knapp RC. Pros and cons of gynecologic tumor markers. Cancer 1987; 60: 1984.

    PubMed  Google Scholar 

  86. Mazurek A, Niklinski J, Laudanski T, et al. Clinical tumour markers in ovarian cancer. Euro Cancer Prevention 1998; 7: 2335.

    Google Scholar 

  87. Maggino T, Sopracordevole F, Matarese M, et al. CA-125 serum level in the diagnosis of pelvic masses: comparison with other methods. Eur J Gynaecol Oncol 1987; 8: 590–595.

    PubMed  CAS  Google Scholar 

  88. Zurawski VR, Broderick SF, Pickens P, et al. Serum CA 125 levels in a group on nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 1987; 69: 606–611.

    PubMed  Google Scholar 

  89. Tholander B, Taube A, Lindgren A, et al. Pretreatment serum levels of CA 125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: influence of histological type, grade of differentiation, and clinical stage of disease. Gynecol Oncol 1990; 39: 26–33.

    PubMed  CAS  Google Scholar 

  90. Hempling RE. Tumor markers in epithelial ovarian cancer. Ob-stet Gynecol Clin North Am 1994; 21: 41.

    CAS  Google Scholar 

  91. Barber HR. Ovarian cancer: Cause diagnosis and treatment. Compr Ther 1987; 13: 25.

    PubMed  CAS  Google Scholar 

  92. Mogensen O. Prognostic value of CA 125 in advanced ovarian cancer. Gynecol Oncol 1992; 44: 207–212.

    PubMed  CAS  Google Scholar 

  93. Fioretti P, Gadducci A, Ferdeghini M, et al. Concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol 1992; 44: 155–160.

    PubMed  CAS  Google Scholar 

  94. Bast RC, Jr., Klug TL, St. John E. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 390: 883.

    Google Scholar 

  95. Niloff JM, Knapp RC, Lavin PT, et al. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gyneocl 1986; 155: 56–60.

    CAS  Google Scholar 

  96. Halila H, Lehtovirta P, Stenman UH. Tumor associated trypsin inhibitor (TATI) in ovarian cancer. Br J Cancer 1988; 57: 304–307.

    PubMed  CAS  Google Scholar 

  97. Ward BG, McGuckin MA, Ramm LE, et al. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CAl25 assay. Cancer 1993; 71: 430–438.

    PubMed  CAS  Google Scholar 

  98. Cole LA, Wang Y, Elliott M. Uriniary human chorionic gonadotropin free B-subunit and B-core fragment: A new marker of gynecological cancer. Cancer Res 1988; 48: 1356.

    PubMed  CAS  Google Scholar 

  99. Anderson T, Waldmann TA, Javadpour N, Glatstein E. Testicular germ-cell neoplasms: Recent advances in diagnosis and therapy. Ann Intern Med 1979; 90: 373.

    Google Scholar 

  100. Doherty AP, Bower M, Christmas TJ. The role of tumour markers in the diagnosis and treatment of testicular germ cell cancers. Brit J Urol 1997; 79 (21): 247–252.

    PubMed  CAS  Google Scholar 

  101. Weissbach L, Bussar-Maatz R, Mann K, et al. The value of tumor markers in testicular seminomas. Eur Urol 1997; 32: 16–22.

    PubMed  CAS  Google Scholar 

  102. Fossa A, Fossa SD. Serum lactate dehydrogenase and human choriogonadotrophin in seminoma. Br J Urol 1989; 63: 408–415.

    PubMed  CAS  Google Scholar 

  103. Dean RC, Moul JW. New Tumor Markers of Testis Cancer. Urol Clin North Am 1998; 25 (31): 365–373.

    PubMed  CAS  Google Scholar 

  104. Rustin GJS, Vogelzang NJ, Sleijfer DT, et al. Consensus statement on circulating tumour markers and staging patients with germ cell tumours. In: EORTC genitourinary group monograph 7: Prostate Cancer and Testicular Cancer. New York: Wiley-Liss 1990; 277–284.

    Google Scholar 

  105. Stoter G, Bosl GJ, Droz JP, et al. Prognostic factors in metastatic germ cell tumours. In: EORTC genitourinary group monograph 7: Prostate Cancer and Testicular Cancer. New York: Wiley-Liss, 1990; 313–319.

    Google Scholar 

  106. Birch R, Williams S, Cone A. Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 1987; 4: 400.

    Google Scholar 

  107. Rathmell AJ, Brand IR, Carey BM, et al. Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit. Clin Oncol R Coll Radiol 1993; 5: 34–38.

    PubMed  CAS  Google Scholar 

  108. Bosl GJ, Geller NL, Cirrincione C, et al. Multivariate analysis of prognostic variables in patients with metastitic testicular cancer. Cancer Res 1983; 43: 3403–3407.

    PubMed  CAS  Google Scholar 

  109. Bagshawe KD, Wass M, Searle F. Markers in gynaecological cancer. Arch Gynecol 1980; 229: 303.

    PubMed  CAS  Google Scholar 

  110. Zarate A and MacGregor C. Beta-subunit HCG and the control of trophoblastic disease. Semin Oncol 1982; 9: 187.

    PubMed  CAS  Google Scholar 

  111. Gion M, Mione R, Leon A, et al. Comparison of the Diagnostic Accuracy of CA27–29 and CA 15–3 in Primary Breast Cancer. Clin Chem 1999; 45 (5): 630–637.

    PubMed  CAS  Google Scholar 

  112. Paterna LR, Arnaiz F, Estenoz J, et al. Study of serum tumor markers CEA, CA 15–3 and CA 27–29 as diagnostic parameters in patients with breast carconoma. Int J Biol Markers 1995; 10: 24–29.

    Google Scholar 

  113. Chan DW, Beveridge RA, Muss H, et al. Use of Truquant BR Radioimmunoassay for Early Detection of Breast Cancer Recurrence in Patients With Stage I and Stage II Disease. J Clin On-col 1997;15(16):2322–2328.

    CAS  Google Scholar 

  114. Bukholm IK, Nesland JM, Karesen R, et al. E-Cadherin and alpha, beta, gamma-catenin protein expression in relation to metastasis in human breast carcinoma. J Pathol 1998; 185 (31): 262–266.

    PubMed  CAS  Google Scholar 

  115. Tetu B, Brisson J, Lapointe H, et al. Prognostic significance of stromelysin 3, gelatinase A, and urokinase expression in breast cancer. Human Pathology 1998; 29 (91): 979–985.

    PubMed  CAS  Google Scholar 

  116. Ganz PA, Ma PY, Wang HI and Elashoff RM. Evaluation of three biochemical markers for serially monitoring the therapy of small-cell lung cancer. J Clin Oncol 1987; 5: 472.

    PubMed  CAS  Google Scholar 

  117. Wibe E, Hannisdal E, Paus E, et al. Neuron-specific enolase as a prognostic factor in metastatic malignant melanoma. Eur J Cancer 1992; 28: 1692–1695.

    Google Scholar 

  118. Tofani A, Cioffi RP, Sciuto R, et al. S-100 and NSE as Serum Markers in Melanoma. Acta Oncologica 1997; 36 (71): 761–764.

    PubMed  CAS  Google Scholar 

  119. Schultz ES, Diepgen TL, Von Den Driesch P. Clinical and prognostic relevance of serum S-100 (beta) protein in malignant melanoma. Br J Dermatol 1998; 138 (31): 426–430.

    PubMed  CAS  Google Scholar 

  120. Kelley MC, Jones RC, Gupta RK, et al. Tumor Associated Antigen TA-90 Complex Assay Predicts Subclinical Metastases and Survival for Patients with Early Stage Melanoma. Cancer 1998; 83 (7): 1355–1361.

    PubMed  CAS  Google Scholar 

  121. Raj GV, Moreno JG, Gomella LG. Utilization of polymerase chain reaction technology in the detection of solid tumors. Cancer 1998; 82 (8): 1419–1442.

    PubMed  CAS  Google Scholar 

  122. Mellado B, Colomer D, Castel T, Munoz M, Carballo E, Galan M, Mascaro JM, Vives-Corrons JL, Grau JJ, Estape J. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis. J Clin Oncol 1996; 14 (71): 2091–2097.

    PubMed  CAS  Google Scholar 

  123. Palmieri G, Strazzullo M, Ascierto PA, Satriano SMR, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. J Clin Oncol 1999; 17 (1): 304–311.

    PubMed  CAS  Google Scholar 

  124. Glaser R, Rass K, Seiter S, Hauschild A, Christophers E, Tilgen W. Detection of circulating melanoma cells by specific amplification of tyrosinase complementary DNA is not a reliable tumor marker in melanoma patients: A clinical two-center study. J Clin Oncol 1997; 15 (8): 2818–2825.

    PubMed  CAS  Google Scholar 

  125. Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The surgical treatment of medullary thyroid carcinoma. Sem Surg Oncol 1999; 16: 50–63.

    CAS  Google Scholar 

  126. Chi DD, Moley JF. Medullary thyroid carcinoma: Genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin North Am 1998;7(4):681–706.

    CAS  Google Scholar 

  127. Guiffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. A review. Ann Oncol 1998; 9: 695–701.

    Google Scholar 

Download references

Authors
  1. Syed Ahmad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Merrick I. Ross
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of California, San Francisco, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  2. Surgical Service, San Francisco VA Medical Center, San Francisco, California, USA

    Jeffrey A. Norton MD (Professor and Vice-Chairman of Surgery, Chief) (Professor and Vice-Chairman of Surgery, Chief)

  3. Division of General Surgery, Duke University Medical Center, Durham, North Carolina, USA

    R. Randal Bollinger MD, PhD (Professor of Surgery, Professor of Immunology, Chief) (Professor of Surgery, Professor of Immunology, Chief)

  4. Division of Surgical Oncology, University of Michigan, Comprehensive Cancer Center, Ann Arbor, Michigan, USA

    Alfred E. Chang MD (Chief, Hugh Cabot Professor of Surgery) (Chief, Hugh Cabot Professor of Surgery)

  5. Department of Surgery, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA

    Stephen F. Lowry MD (Professor and Chairman) (Professor and Chairman)

  6. Division of General Surgery, University of California, San Francisco, San Francisco, California, USA

    Sean J. Mulvihill MD (Professor of Surgery, Chief) (Professor of Surgery, Chief)

  7. Karmanos Cancer Institute, Wayne State University, Harper Hospital, Detroit, Michigan, USA

    Harvey I. Pass MD (Professor of Surgery and Oncology, Chief of Thoracic Oncology) (Professor of Surgery and Oncology, Chief of Thoracic Oncology)

  8. Cell Biology and Physiology, Washington University School of Medicine, St. Louis, Missouri, USA

    Robert W. Thompson MD (Associate Professor of Surgery) (Associate Professor of Surgery)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ahmad, S., Ross, M.I. (2001). Tumor Markers. In: Norton, J.A., et al. Surgery. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-57282-1_74

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-57282-1_74

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63239-6

  • Online ISBN: 978-3-642-57282-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation